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Abstract: Colorectal carcinoma is among the most common types of cancers. With this disease,
diffuse scattering in the abdominal area (peritoneal carcinosis) often occurs before diagnosis, making
surgical removal of the entire malignant tissue impossible due to a large number of tumor nodules.
Previous treatment options include radiation and its combination with intraperitoneal heat-induced
chemotherapy (HIPEC). Both options have strong side effects and are often poor in therapeutic
efficacy. Tumor cells often grow and proliferate dysregulated, with enzymes of the protein kinase
family often playing a crucial role. The present study investigated whether a combination of protein
kinase inhibitors and low-dose induction of oxidative stress (using hydrogen peroxide, H2O2) has
an additive cytotoxic effect on murine, colorectal tumor cells (CT26). Protein kinase inhibitors
from a library of 80 substances were used to investigate colorectal cancer cells for their activity,
morphology, and immunogenicity (immunogenic cancer cell death, ICD) upon mono or combination.
Toxic compounds identified in 2D cultures were confirmed in 3D cultures, and additive cytotoxicity
was identified for the substances lavendustin A, GF109203X, and rapamycin. Toxicity was concomitant
with cell cycle arrest, but except HMGB1, no increased expression of immunogenic markers was
identified with the combination treatment. The results were validated for GF109203X and rapamycin
but not lavendustin A in the 3D model of different colorectal (HT29, SW480) and pancreatic cancer
cell lines (MiaPaca, Panc01). In conclusion, our in vitro data suggest that combining oxidative stress
with chemotherapy would be conceivable to enhance antitumor efficacy in HIPEC.
Keywords: anticancer drugs; pancreatic cancer; screening; tumor spheroids
1. Introduction
Colorectal carcinoma is among the most common cancers in both men and women. Risk factors
are smoking and obesity, besides a lack of exercise and a diet low in carbohydrates but rich in alcohol
and red meat diet is to be named as a risk factor. Moreover, genetic predisposition may put some
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patients at risk [1,2]. The relative 5-year survival rates are 63% in men and 63% in women. However,
the prognosis is highly dependent on the stage at diagnosis. Unfortunately, diffuse metastasis in
the abdomen is often present before diagnosis [3,4]. This complication of peritoneal carcinomatosis
(PC), in particular, is associated with inferior survival and is still challenging in its treatment [5,6].
Besides colorectal cancer, also other gastrointestinal cancers are able to diffusely metastasize and
create peritoneal carcinomatosis. Especially the pancreas carcinoma is such a tremendous disease with
meager survival rates [7–9]. Even with surgical R0 resection (a histologically confirmed complete
removal of the primary tumor), auxiliary organ infiltrations can occur because tumor nodules are not
easy to differentiate visually from the surrounding tissue [10]. In contrast to localized tumors, a variety
of side effects, such as infiltration of the liver and lungs, blockage of the bile duct, or the pancreas,
can arise in PC [11,12]. In addition to the attempt of surgical resection, current treatment regimens
include radiation and HIPEC, intraperitoneal heat-induced chemotherapy [13]. Combinations of
chemotherapeutic agents are often used. However, these two treatment approaches are associated
with severe side effects. The chemotherapeutic agents are often dissolved in a sufficient volume of
sodium chloride that is pumped into the peritoneum to flush the surgical site [14]. The heated fluid is
absorbed through the peritoneum so that it can cause systemic side effects. In addition, many rapidly
mutating tumors develop resistance to specific chemotherapeutic agents [15–19]. Hence, there is a
need for new therapeutic avenues for the peritoneal lavage of patients suffering from PC.
Protein kinases are a group of enzymes that can reversibly transfer a phosphate group to the
hydroxyl group of amino acids in proteins. Together with the counteracting protein phosphatases, they
precisely alter protein function in many cellular processes [20]. Protein kinases can be subdivided into
two major classes, which are either specific for the phosphorylation of Ser/Thr or tyrosine residues [21].
Approximately 2% of the human genome encodes for protein kinases with 518 different protein
kinases known [22]. Besides membrane-bound receptors, which possess a glycosylated extracellular
binding region linked to the cytosolic domain via a single hydrophobic transmembrane domain,
there are also cytoplasmatic protein kinases [23]. Since protein kinases regulate a variety of signaling
pathways, which are particularly vital for cell growth and proliferation [24], they are essential in
physiology but also pathology, e.g., arteriosclerosis [25], diabetes [26], and precancerous lesions, as well
as cancer [27–31]. For example, in cancer, a fusion of a receptor tyrosine kinase with a free tyrosine
kinase leads to long-term oligomerization and activation, as in BCR-ABL fusion in chronic myeloid
leukemia [32]. Furthermore, point mutations can lead to increased sensitivity to a ligand or even
activation without a ligand, as in acute myeloid leukemia [33]. In some forms of breast cancer, there is
overexpression of the receptor itself (HER-2/neu) [28].
Therefore the ‘kinome’, which is the complete set of protein kinases, has become an attractive
target in cancer treatment with today 49 FDA-approved protein kinase inhibitors in clinical use. Small
molecules modulate the catalytic activity by altering the binding of ATP or the kinases’ substrates.
Antibodies can be directed against protein kinase ligands, their binding, or the receptor itself. Inhibiting
the dimerization of the receptor tyrosine kinases, which is a crucial mechanism for their activation,
can also be a target [27,30,31,34]. One specific target is epithelial growth factor receptor (EGFR), being
responsible for cell proliferation, survival, motility, and cell cycle regulation. In many cancers—such as
glioma, pancreatic carcinoma, ovarian cancer, breast cancer, small cell lung cancer, and up to 77% of
colorectal cancers—EGFR is mutated and dysregulated [27,35]. After ligand binding, such as EGF or
TGFβ, dimerization of the receptor and phosphorylation of tyrosine residues in the cytosolic domain
occurs [36]. This phosphorylation allows several signal paths, such as the Ras/Raf/Erk, PI3K/Akt, PLC,
and JAK/STAT signal path, to be activated [37]. In clinical trials, the anti-receptor antibodies cetuximab
and panitumumab led to a better prognosis in 10% of patients with metastatic colorectal carcinoma [38].
This underlines the importance of such pathological changes and targeted pharmacological therapy [39].
Another target is protein kinase C (PKC) that is activated by growth factor-mediated phospholipase C
(PLC) and is involved in many signaling processes. Downstream targets are mostly unknown, but the
most important is thought to be Erk, GSK-3ß, NfκB, and the p-glycoprotein [40–43]. Hence, PKC is
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involved in many signaling pathways and therefore becomes interesting in its pathological upregulation
and constant activation. For example, invasion and increased proliferation of intestinal cancer cells
are associated with upregulation of PKCß [44–46]. Here, somatic mutations of the enzyme have
been observed with the δ isotype being upregulated compared to non-malignant tissue [47]. Various
PKC inhibitors have been tested in human phase I–III studies, but their efficiency has unfortunately
been low which is likely due to limited bioavailability of the tested substances [48,49]. An additional
target is Janus kinase 3 (Jak-3)which belongs to the Janus family of kinases and is most commonly
expressed in hematopoietic but also in intestinal epithelial cells. Janus kinases are non-receptor tyrosine
kinases, which are essential in the signal transduction of cytokine receptors as they have no intrinsical
catalytic activity. In colorectal carcinoma, the dysregulation of JAK3 leads to increased invasion and
progressive growth [50]. In 2012, the first JAK inhibitor, Ruxolitinib, was approved for the treatment
of myelofibrosis and polycythemia vera so that further inhibitors are being investigated as potential
treatment approaches in other types of cancer e.g., colorectal cancer [51–53]. Here, inhibition of JAK3
induced apoptosis and cell cycle arrest [54]. Metastasis and tumor growth in colorectal carcinoma is
often promoted by a signaling pathway in which the mammalian target of rapamycin (mTOR) plays
a crucial role. A mutation of mTOR is rarely found [55]. Therefore, dysregulation of this signaling
pathway often is a cause of cancer [56]. In 23% of patients with colorectal carcinoma, a mutation
of phosphatidylinositol-3-kinase (PI3K) can be detected [57]. This enzyme is negatively regulated
by the phosphatase and tensin homologous (PTEN). If there is a mutation in the enzyme and too
little PTEN activity, this results in increased activation of the tyrosine kinase mTOR [56]. Another
regulatory step in mTOR activity is the Akt kinase. This kinase is, on the one hand, phosphorylated by
the mTOR complex-2, but at the same time, regulates the activity of the mTOR complex-1 together
with the PI3K and PTEN. All of these proteins were found in higher quantities in the context of
colorectal carcinoma than in healthy tissue [58]. Increased mTOR activation leads to tumor growth [59],
while mTOR inactivation reduces tumor growth in colorectal carcinoma [60,61]. Several mTOR
inhibitors, like everolimus and temsirolimus, are used in treatment of breast cancer or renal cell
carcinoma. Nevertheless, despite this great variety of inhibitors in cancer treatment, problems with
drug resistance, reduced efficacy, and toxicity remain challenging in oncology [22]. Hence signaling
pathways such as the mTOR pathway are also linked to reactive oxygen species (ROS). A combination
of both could enhance the efficiency of specific protein kinase inhibitors [62].
ROS take part in crucial physiological cell functions, signaling pathways, and biochemical reactions.
Non-malignant cells are in a balance of such reactions. This is mainly due to enzymes such as glutathione
peroxidase and catalase, which can detoxify ROS [63,64]. For this study, we utilized low-dose hydrogen
peroxide (50 µM H2O2) in a concentration where oxidative stress was induced without necrotizing
cells. High concentrations are used clinically to disinfect skin or wounds at concentrations of 3% H2O2,
which corresponds to 1 M. H2O2 is not an approved drug but notwithstanding a well-investigated
molecule in cell and cancer biology. With low-dose H2O2, the antioxidant enzyme catalase is able
to decompose H2O2 into water and oxygen [65–67]. Healthy cells contain about 10 nM H2O2 [68]
and have a relatively high catalase activity. In contrast, many cancer cells have a 10 to 100-fold
lower catalase activity [69]. The concentration of intracellular H2O2 depends primarily on the
activity of this enzyme and the permeability of the cell membrane to extracellular H2O2 [63,70].
Compared to non-malignant cells, cancer cells often express more aquaporins through which H2O2
can enter [71]. At supra-physiological concentrations of H2O2, oxidation can damage DNA and
lipids as well as denature, unfold, or alter the conformation of proteins and enzymes, thereby
compromising their function. Dysfunctional proteins accumulate within the cell and cause stress,
which can ultimately lead to cell death [66,72]. These mechanisms are generally summarized by the
term cellular senescence [73]. Ultimately, these events can be fatal for cancer cells. For example,
H2O2-enriching pharmaceuticals are under current investigation [74–76]. Moreover, the induction of
oxidative stress is also one principle of photodynamic therapy (PDT) [77–79], ionizing radiation [80,81],
or cold physical plasma [82,83]. Being a novel medical technology, medical plasmas utilize the
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generation of various ROS to tackle cancer, which was already successful in the treatment of patients
with head and neck cancer [84,85]. Accordingly, several chemical and biological effects can be abrogated
by adding ROS scavengers [86–88]. ROS-induced cancer cell death can also be highly immunogenic [89]
(immunogenic cell death, ICD). Plasma treatment can induce ICD as well [90]. Specifically, cells
subjected to ICD can foster antigen-specific immune responses against tumor-associated antigens
and neoantigens [91–93]. This is preceded by activation of professional antigen-presenting cells via
danger-associated molecular patterns (DAMPs) such as calreticulin (CRT), heat-shock protein 70 and
90 (HSP70, HSP90, and high-mobility group box 1 protein (HMGB1) [92]. Hence, ICD has significant
potential in cancer therapy, in that tumors can be tackled that have previously escaped an endogenous
immune response [94–96]. ICD may have a positive prognostic value [97] as a basis to generate T-cell
responses, which are supported via checkpoint immunotherapy.
The aim of this study was to screen a protein kinase inhibitor library of 80 compounds against
additive cytotoxicity with H2O2 in colorectal cancer cells with the vision to improve current HIPEC in
patients suffering from PC. By studying several cytotoxicity and ICD parameters in 2D or 3D tumor
models, we were able to identify two targets that may be potential candidates for such an approach.
2. Results
2.1. Screening a Library of 80 Different Kinase Inhibitors Identified Four Substances with Additive Toxicity in
Combination with H2O2
Kinase inhibitors are regularly used in the therapy of various cancers. In this study, 80 different
substances were used to identify drugs that have significantly added toxicity upon the combination
with low-dose H2O2 in vitro. During the experimental procedures, the most intoxicating substances
were identified after three selection steps, and substance codes were used to analyze in a blinded
fashion (Figure 1a). The code was kept for labeling graphs to enhance readability. The respective
substances can be found in Table 1. Incubating CT26 colorectal cancer cells with tyrosine kinases
either reduced the cells’ metabolic activity in a dose-dependent fashion (Figure 1b), did not reduce
their metabolic activity (Figure 1c), or did not produce a clear dose–response relationship (Figure 1d).
First, a specific dose for each substance was selected in this experiment, where the target was a 50%
reduction compared to untreated control. Second, the substances were combined with low-dose
H2O2 (50 µM), and the cancer cells’ metabolic activity was assessed 24 h later to identify additive
cytotoxic effects (Figure 1e). The low-dose of H2O2 was used to induce oxidative stress to the cells
in the absence of excessive cytotoxicity. In combination, some tyrosine kinase inhibitors were not
superior to H2O2 alone, where others significantly reduced the metabolic activity in an additive to
synergistic fashion. The sequence of treatment (first drug, then H2O2, or first H2O2, then drug) was
found to be negligible (Supplementary Figure S1a–b). Subsequently, all inhibitors were chosen for
further investigation (second selection) that led in combination with H2O2 to a >75% reduction of
metabolic activity compared to H2O2 alone (for the concentrations, see Supplementary Table S1). These
substances (B9, C9, C10, D7, G1, G4, G7, and H8) were investigated in more detail. In both settings,
substances alone, and substances + H2O2, a reduction was observed for the tested colorectal cancer
cells (Figure 1f). Calculating the fold change of mono vs. combination therapy, four substances (B9,
D7, G4, and H8 at 100 µM) gave a more than 1.5-times higher reduction of the cancer cells metabolic
activity compared to the substances alone (Figure 1g). Especially H8 developed a strong synergistic
effect with H2O2 and was almost 4-times more effective than in monotherapy. Before further testing
these four most interesting protein kinase inhibitors, its effect on non-malignant HaCaT keratinocytes
was tested in combination with 50 µM H2O2. The combinational regimen reduced the metabolic
activity of the non-malignant cells but did not reach the target line as it was applied for CT26 cancer
cells (Figure 1h). Hence, if non-malignant cells would have been utilized for this screening, the four
selected inhibitors would not have been identified as effective and would not have been selected.
Additionally, to confirm that the utilized doses of H2O2 are semi-toxic, HaCaT keratinocytes were
exposed to different concentrations of up to 200 µM. All tested concentrations induced only a mild
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reduction in the metabolic activity, while at twice (100 µM) of the concentration used for the screening,
a 25% reduction was observed (Figure 1i).Cancers 2020, 12, 122 7 of 26 
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inhibitor library; representative drugs that show (b) dose-dependent, (c) no, or (d) an odd effect on 
the reduction of cancer cell metabolic activity 24 h post-incubation with the kinase inhibitors and the 
concentration that was chosen to reach 50% of reduction (blue arrows); (e) metabolic activity of cancer 
cells with its numerical value that had received kinase inhibitors together with H2O2 for 24 h (red: 
substances that reached 75% reduction in combination with H2O2; crossed fields: no substances 
tested); (f) detail view of the cancer cell metabolic activity +SEM 24 h post-incubation with substances 
alone or in combination with H2O2; (g) increase of metabolic activity reduction +SEM of substances + 
H2O2 compared to substances alone, and selection (red line) of four inhibitors with a fold change of 
this increase >1.5 (colored bars); (h) metabolic activity of non-malignant HaCaT keratinocytes that 
received the four selected kinase inhibitors alone or in combination with H2O2; (i) metabolic activity 
of non-malignant HaCaT keratinocytes exposed to H2O2 in different concentrations. Significance 
levels for the comparison of substances without H2O2 to the respective substances with H2O2 (δ), and 
of their combination (with H2O2) to the H2O2-alone control (*) were determined via ANOVA. Data are 
representatives out of three (b–e) or two (f–i) independent replicates. 
2.2. Combination of Selected Kinase Inhibitors with H2O2 Reduced Cell Growth and Increased Cytotoxicity 
Assessment of metabolic activity is not equal to cell death nor cell proliferation. To analyze these 
cellular traits in more detail, the four previously selected kinase inhibitors (B9: lavendustin A; D7: 
GF109203X; G4: ZM449829; H8: rapamycin) were investigated regarding their potential of reducing 
cellular growth and increasing cytotoxicity. Twenty-four hours post-exposure, all four tested 
Figure 1. Experimental procedures and selection of kinase inhibitors. (a) Experimental strategies for
the identification of selected kinase inhibitors with synergistic effect with H2O2 out of a 80 compound
inhibitor library; representative drugs that show (b) dose-dependent, (c) no, or (d) an odd effect on
the reduction of cancer cell metabolic activity 24 h post-incubation with the kinase inhibitors and
the concentration that was chosen to reach 50% of reduction (blue arrows); (e) metabolic activity of
cancer cells with its numerical value that had received kinase inhibitors together with H2O2 for 24 h
(red: substances that reached 75% reduction in combination with H2O2; crossed fields: no substances
tested); (f) detail view of the cancer cell metabolic activity +SEM 24 h post-incubation with substances
alone or in combination with H2O2; (g) increase of metabolic activity reduction +SEM of substances
+ H2O2 compared to substances alone, and selection (red line) of four inhibitors with a fold change
of this increase >1.5 (colored bars); (h) metabolic activity of non-malignant HaCaT keratinocytes that
received the four selected kinase inhibitors alone or in combination with H2O2; (i) metabolic activity of
non-malignant HaCaT keratinocytes exposed to H2O2 in different concentrations. Significance levels
for the comparison of substances without H2O2 to the respective substances with H2O2 (δ), and of
their combination (with H2O2) to the H2O2-alone control (*) were determined via ANOVA. Data are
representatives out of three (b–e) or two (f–i) independent replicates.
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Table 1. Overview of the kinase inhibitors utilized in this study. Listed are all inhibitors used in this
study, their substance code used throughout the figures and text, the target structure of the inhibitors,
and the CAS number.
Substance Code Name Kinase Target CAS
B1 PD-98059 MEK 167869-21-8
B2 U-0126 MEK 109511-58-2
B3 SB-203580 p38 MAPK 152121-47-6
B4 H-7·2HCl PKA, PKG, MLCK, PKC 84477-87-2
B5 H-9·HCl PKA, PKG, MLCK, PKC 116970-50-4
B6 Staurosporine Pan-specific 62996-74-1
B7 AG-494 EGFRK, PDGFRK 133550-35-3
B8 AG-825 HER1-2 149092-50-2
B9 Lavendustin A EGFRK 125697-92-9
B10 RG-1462 EGFRK 136831-49-7
B11 TYRPHOSTIN 23 EGFRK 118409-57-7
B12 TYRPHOSTIN 25 EGFRK 118409-58-8
C1 TYRPHOSTIN 46 EGFRK, PDGFRK 122520-85-8
C2 TYRPHOSTIN 47 EGFRK 122520-86-9
C3 TYRPHOSTIN 51 EGFRK 122520-90-5
C4 TYRPHOSTIN 1 Negative control fortyrosine kinase inhibitors 2826-26-8
C5 TYRPHOSTIN AG 1288 Tyrosine kinases 116313-73-6
C6 TYRPHOSTIN AG 1478 EGFRK 175178-82-2
C7 TYRPHOSTIN AG 1295 Tyrosine kinases 71897-07-9
C8 TYRPHOSTIN 9 PDGFRK 10537-47-0
C9
Hydroxy-2-
naphthalenylmethylphosphonic
acid
IRK 120943-99-9
C10 PKC-412 PKC inhibitor 120685-11-2
C11 Piceatannol Syk 10083-24-6
C12 PP1 Src family 172889-26-8
D1 AG-490 JAK-2 133550-30-8
D2 AG-126 IRAK 118409-62-4
D3 AG-370 PDGFRK 134036-53-6
D4 AG-879 NGFRK 148741-30-4
D5 LY 294002 PI 3-K 154447-36-6
D6 Wortmannin PI 3-K 19545-26-7
D7 GF 109203X PKC 133052-90-1
D8 Hypericin PKC 548-04-9
D9 Ro 31-8220 mesylate PKC 138489-18-6
D10 D-erythro-sphingosine PKC 123-78-4
D11 H-89·2HCl PKA 127243-85-0
D12 H-8 PKA, PKG 84478-11-5
E1 HA-1004·HCl PKA, PKG 92564-34-6
E2 HA-1077·2HCl PKA, PKG 103745-39-7
E3
2-Hydroxy-5-(2,5-
dihydroxybenzylamino)benzoic
acid
EGFRK, CaMK II 125697-93-0
E4 KN-62 CaMK II 127191-97-3
E5 KN-93 CaMK II 139298-40-1
E6 ML-7·HCl MLCK 109376-83-2
E7 ML-9·HCl MLCK 105637-50-1
E8 2-aminopurine p58 PITSLRE β1 452-06-2
E9 N9-isopropyl-olomoucine CDK 158982-15-1
E10 Olomoucine CDK 101622-51-9
E11 Iso-olomoucine Negative control forOlomoucine 101622-50-8
E12 Roscovitine CDK 186692-46-6
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Table 1. Cont.
Substance Code Name Kinase Target CAS
F1 5-iodotubericidin ERK2, adenosine kinase,CK1, CK2, 24386-93-4
F2 LFM-A13 BTK 62004-35-7
F3 SB-202190 p38 MAPK 152121-30-7
F4 PP2 Src family 172889-27-9
F5 ZM 336372 cRAF 208260-29-1
F6 SU 4312 Flk1 5812-07-7
F7 AG-1296 PDGFRK 146535-11-7
F8 GW 5074 cRAF 220904-83-6
F9 Palmitoyl-DL-carnitine PKC 6865-14-1
F10 Rottlerin PKC∆ 82-08-6
F11 Genistein Tyrosine kinases 446-72-0
F12 Daidzein Negative control forGenistein 486-66-8
G1 Erbstatin analogue EGFRK 63177-57-1
G2 Quercetin·2H2O PI 3-K 6151-25-3
G3 SU1498 Flk1 168835-82-3
G4 ZM 449829 JAK-3 4452-06-6
G5 BAY 11-7082 IKK signaling pathway 195462-67-7
G6 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole CK II 53-85-0
G7
2,2′,3,3′,4,4′-hexahydroxy-1,1′-
biphenyl-6,6′-dimethanol
dimethyl ether
PKCα, PKCγ 154675-18-0
G8 SP 600125 JNK 129-56-6
G9 Indirubin GSK-3β, CDK5 479-41-4
G10 Indirubin-3′-monooxime GSK-3β 160807-49-8
G11 Y-27632·2HCl ROCK 146986-50-7
G12 Kenpaullone GSK-3 β 142273-20-9
H1 Terreic acid BTK 121-40-4
H2 Triciribine Akt signaling pathway 35943-35-2
H3 BML-257 Akt 32387-96-5
H4 SC-514 IKK2 354812-17-2
H5 BML-259 Cdk5/p25 267654-00-2
H6 Apigenin CK-II 520-36-5
H7 BML-265 EGFRK 28860-95-9
H8 Rapamycin mTOR 53123-88-9
2.2. Combination of Selected Kinase Inhibitors with H2O2 Reduced Cell Growth and Increased Cytotoxicity
Assessment of metabolic activity is not equal to cell death nor cell proliferation. To analyze these
cellular traits in more detail, the four previously selected kinase inhibitors (B9: lavendustin A; D7:
GF109203X; G4: ZM449829; H8: rapamycin) were investigated regarding their potential of reducing
cellular growth and increasing cytotoxicity. Twenty-four hours post-exposure, all four tested inhibitors
significantly reduced the number of cancer cells if combined with H2O2 (Figure 2a). A similar effect
was observed analyzing the cellular growth area of the cancer cells (Figure 2b), finding all substances
combined with H2O2 to reduce the cytosolic area significantly compared to H2O2 or the substances
alone (Figure 2c). The most substantial growth inhibition was observed for H8 + H2O2. To analyze
terminal cell death, colorectal cancer cells were stained with Sytox (Figure 2d). Using algorithm-based
object segmentation and analyzing each object’s Sytox intensity, dramatic terminal cell death was
observed for the combination treatment and to a lesser extent, for drug monotherapy (Figure 2e).
This suggested that the drug monotherapies are cytostatic, whereas the combination treatment was
cytotoxic. H2O2 was used at a pre-determined low-dose concentration (50 µM), which did not induce
terminal cell death in our treatment regimen (Figure 2f light grey bar). Hence, we conclude a synergistic
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cytotoxic effect for the combination therapy of tyrosine kinase inhibitors and low-dose H2O2. Another
way to generate a plethora of reactive oxygen species, such as hydrogen peroxide, in parallel is
the exposure of the cells to cold physical plasmas. Such plasmas, as induced by different devices
as the kINPen or Plasma Soft Jet, lead to a time-dependent induction of H2O2 in the cell culture
medium, which showed to reduce the metabolic activity of different cells (Supplementary Figure S2a–b).
The treatment times that were needed for the deposition of 50 µM H2O2 did vary between the jets (43 s
to 53 s) outlining their different structures. Moreover, these plasmas changed the morphology and
growth of the cells similarly to H2O2 and can be considered for further use in similar combinations
(Supplementary Figure S2c–e).
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2.3. Combination of Selected Kinase Inhibitors with H2O2 Leads to Morphological Alterations, Cell Cycle
Arrest, and Modulated Surface Marker Expression
The effects on metabolic activity and viability may correlate with functional or morphological
alterations in cancer cells. To address this, colorectal cancer cells treated with the four selected tyrosine
kinase inhibitors (+/− H2O2), and detailed microscopic analysis of cellular morphology (Figure 3a)
was performed. The treatment regimens introduced changes from spindle-like (untreated control) to
elongated (H2O2 alone) and rounded shaped cells (drug mono and combination treatment) (Figure 3b).
Surprisingly, adding H2O2 to the substances B9: lavendustin A and H8: rapamycin significantly increased
their morphology towards shifting to a rounded cell type, whereas combination with D7: GF109203X and
G4: ZM449829 did not produce such an effect (Figure 3b). The extent of such rounding may change in
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the kinetic of the post-treatment but when investigated at the same time point as all other assays still give
valuable information on the cellular changes observed. In parallel, the single-cell area was quantified
using algorithm-based image segmentation tools. Exposing the cells to H2O2 alone led to a significant
decrease in individual cell size when compared to untreated control cells (Figure 3c). By contrast,
an increase in individual cell area was observed upon incubation with the kinase inhibitors and in
combination with H2O2. For combination treatment, this effect was enhanced in tendency compared
to drug monotherapy (B9: lavendustin A, D7: GF109203X, and G4: ZM449829) and significantly for
H8: rapamycin (Figure 3c). The results were obtained from more than 2000 individual cells segmented
per condition. The increase in individual cells’ size can be a hallmark of cellular senescence and cell
cycle arrest. Using nuclear acid staining and algorithm-based cell cycle phase analysis (Figure 3d),
the number of colorectal cancer cells halted in the G2 phase was elevated in all treatment regimens,
including H2O2 alone (Figure 3e). Combination vs. drug monotherapy gave an increase with all
four drugs. To analyze the potential immunogenic consequences of the cytotoxic treatment regimens,
multicolor flow cytometry was performed assessing the expression of several DAMPs important to elicit
antitumor immunity. Compared to untreated cells and cells that were exposed to H2O2 alone, only
modest modulation of cell surface markers was observed, ranging from 0.9- to 1.1-fold change (Figure 3f).
Normalizing each combination treatment to H2O2 mono treatment (Figure 3g–j), significant upregulation
was seen for HMGB1 in for all four combination treatments. HSP90 was increased in tendency for all
for drug-H2O2 combination treatment when compared to drug alone. For CRT, a similar increase was
observed, while HSP70 was only increased in tendency for D7: GF109203X.
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2.4. Only Three Out of Four Selected Kinase Inhibitors Showed Enhanced Toxicity in Combination with H2O2
in 3D Tumor Spheroids
Three-di ensional tumor cell models allow for more cellular heterogeneity and therefore are
regarded as appropriate tools to further test novel antitumor approaches. To validate the combination
treatments of the four compounds with H2O2 that were identified in 2D cultures, 3D colorectal cancer
cell tumor spheroids from CT26 cells were generated. At several time points of exposure to mono
or combination treatments, spheroids were imaged and analyzed using algorithm-based imaging
tools (Figure 4a). A decrease in the spheroid volume was observed at 72 h post-treatment, which was
significant for B9: lavendustin A, G4: ZM449829, and H8: rapamycin plus H2O2 (Figure 4b). Tracking
cytotoxic effects in 3D tumor spheroids during the 72 h time-course revealed an increase of toxicity with
increasing culture time, which was also observed in controls to a modest extent (Figure 4c). However,
quantitative image analysis revealed a substantial (60-fold) increase in cytotoxicity in colorectal cancer
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cells that were incubated with H8: rapamycin + H2O2 (Figure 4d), which was significantly lower in
the drug mono treatment group (40-fold), and negligible in control spheroids and spheroids receiving
H2O2 alone (4-fold). Similar effects, although to a lesser extent, were observed for the kinase inhibitors
B9: lavendustin A and D7: GF109203X (Figure 4e–f). Only substance G4: ZM449829 failed to induce
a significant toxic effect in tumor spheroids in both mono and combination treatment (Figure 4g).
A summary of the effects observed with all four tyrosine kinase inhibitors in combination with low-dose
H2O2 is presented in Table 2.
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Table 2. Summary table of the key results identified in this study. Shown are the toxicity in 2D and 3D
cultures with the combination treatment of the four in 2D cultures identified drugs, as well as cell cycle
arrest and immunogenic cancer cell death-associated expression of cell surface markers. Effect intensity
was graded (+++ = high, ++ = intermediate, + = modest, - = no effect).
Parameter B9: Lavendustin A D7: GF109203X G4: ZM449829 H8: Rapamycin
Toxicity (2D) + ++ ++ +++
Toxicity (3D) + ++ - +++
Cell cycle arrest + ++ - +
ICD + + + -
2.5. Toxic Effects of Two of Our Three Selected Kinase Inhibitors Were Validated in a 3D Tumor Model
of Different Colorectal and Pancreatic Cancer Cells.
After identifying three kinase inhibitors to actively induce toxicity in tumor spheroids shaped
from CT26 colorectal cancer cells, their anti-tumor capacity needed to be validated in another model
of tumor spheroids. Applying the same treatment regimen to HT29 colorectal cancer cells in a 3D
spheroid culture, increased the Sytox Blue dead cell stain intensity during a 72 h time-course. Especially
the substances D7: GF109203X and H8: rapamycin, together with H2O2, again induced cell death that
was significantly increased compared to H2O2 alone or their respective mono treatment (Figure 5c,e).
However, changes were not as stable as seen before in CT26 spheroids, and B9: lavendustin A and G4:
ZM449829 failed to increase the effect of H2O2 (as seen for B9: lavendustin A where H2O2 exceeds the
combinational treatment, Figure 5b,d). Moreover, cell death was quantified in another colorectal cancer
cell line, SW480 (Figure 5f). All three tested colorectal cancer cell lines responded significantly to the
combination of D7: GF109203X and H8: rapamycin (Figure 5h,j). The SW480 cells were very vulnerable
to the combination treatments with low-dose H2O2, and all combinational regimens were significant
compared to the control at t = 72 h post-treatment, which was not found for the monotherapies with
the inhibitors alone (Figure 5g–j). The best induction of cell death was observed for the inhibitor
D7: GF109203X (Figure 5h). Interestingly, the SW480 spheroids reached a toxicity plateau at t = 24 h,
which then fairly preserved the effect, except for D7: GF109203X, where even after 24 h the toxicity
increased. As these promising findings should not be limited to one tumor entity that can induce
peritoneal carcinomatosis, we further tested the most promising kinase-inhibitors on pancreatic cancer
cell spheroids. Three-dimensional tumor spheroids formed from MiaPaca cells also responded to
the treatment regimen in a time-dependent manner and showed increased Sytox signals after the
72 h time course (Supplementary Figure S3a). All in all the combinational regimen did not cause
induction of toxicity as strong as for CT26 cancer spheroids, but all substances were significantly
more effective in their combination with H2O2 than in their mono treatment (Supplementary Figure
S3b–e). Additionally, the inhibitors B9: lavendustin A, G4: ZM449829, and H8: rapamycin was also
significantly toxic compared to the control regimen (Supplementary Figure S3a). In contrast to the
spheric structure of compact spheroids, Panc01 pancreatic cancer cells form only loose constructions.
(Supplementary Figure S3f). After the exposure of these spheroids to the toxic compounds, destruction
and fragmentation were observed. The combination of H2O2 and B9: lavendustin A, D7: GF109203X
and H8: rapamycin significantly reduced the spheroids’ ‘compactness’ (morphology parameter that
was calculated by the distribution of strong brightfield signals inside the spheroid region) compared to
H2O2 in monotherapy (Supplementary Figure S3g). This parameter was chosen because of technical
limitations in assaying terminally dead cells. Spheroids with many dead cells tend to ‘fall apart’
and by that increase the area and decrease the compactness score, which was quantitated in an
unbiased manner using algorithm-driven image quantification. In every tested substance, this effect
was higher in the combinational regimen and was significant for B9: lavendustin A and D7: GF109203X
(Supplementary Figure S3g). As the second step, the area of this decomposed structure was quantified
using the same software-based analysis tools, and it was found that this destruction is time-dependent
and increased to greatest extend at t = 72 h but also during the whole time-course (as shown as
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AUC: Supplementary Figure S3h–k). All regimens in combination with G4: ZM449829 failed to
induce toxicity in Panc01 spheroids, too, while B9: lavendustin A, D7: GF109203, and H8: rapamycin
developed substantial and significant toxicity with H2O2. Interestingly, B9: lavendustin A and D7:
GF109203X was significantly more effective in the combination as opposed to H8: rapamycin, which
was effective in combinational and also in monotherapy (Supplementary Figure S3k). These findings
suggested the potential of reactive species in combination with two selected kinase inhibitors (D7:
GF109203X and H8: rapamycin) to enhance toxicity in three different (CT26, HT29, Panc01) 3D cancer
spheroid models.
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3. Discussion
The aim of this work was to identify protein kinase inhibitors that acted in an additive or synergistic
manner with H2O2 (itself applied at low-dose, non-toxic conditions) cytotoxic against colorectal cancer
cells. The hypothesis was that a combination of several stress pathways (blockage of growth signals
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together with oxidative stress) leads to additive cytotoxicity in tumor cells. Clinically, this might lead
to a reduction of drug concentrations needed, resulting in a decrease of toxic side effects while at
the same time having similar or even increased therapeutic efficacy. For this purpose, a compound
library of 80 different inhibitors was tested in combination with low-dose H2O2 by assessing various
parameters such as cellular metabolic activity, morphology, cell cycle arrest, immunogenic cell death
(ICD), and cytotoxicity in 2D and 3D in vitro models.
The benefit of targeted therapy is to achieve the most toxic effect possible concerning the tumor
cells without damaging the surrounding tissue and thus limiting the dose of the treatment [98].
However, one cause of the failure of cancer therapy is resistance to chemotherapy. Resistance is
mediated by a high rate of mutations and can develop before or during treatment, i.e., exposure to the
drugs [99]. In many treatment regimens, such as HIPEC, various chemotherapeutic agents are used
in combination [12,14]. Ways to avoid resistance is the use of new chemotherapeutic agents and the
combination with other treatment regimens such as oxidative stress [100] to damage the tumor cells
using several pathways in parallel [101,102]. Especially in the treatment of peritoneal carcinomatosis,
as a complication of colorectal carcinoma, our approach of using H2O2 seems promising since during
HIPEC the abdominal cavity is flushed with heated chemotherapeutic agents [12] that only act locally
but also offer seamless combination with agents other than chemotherapy alone.
Low-dose concentrations of ROS, as we used in our experiments, are able to interfere in various
cellular signaling processes. Several redox-sensitive target molecules can be activated or inactivated
by even mild changes in the intracellular redox state. On target molecule is thioredoxin (Trx), which,
under normal conditions, inhibits the apoptosis signaling regulating kinase 1 (ASK1), also known as
mitogen-activated protein kinase 5 (MAP3K5). Rising ROS concentrations induce Trx dimerization [103]
and, therefore, dissociation of the ASK1/Trx complex leading to the activation of several downstream
targets like MKK3/7, MKK4/MKK7, p38, and JNK which are part of the mitogen-activated protein
kinase pathway [104–107]. As such, ASK-1 as well as its downstream targets, are crucial in a variety
of cellular responses to oxidative stress, e.g., apoptosis, differentiation, and inflammation. Both
p38 and JNK can also be directly activated after exposure to low micromolar hydrogen peroxide
concentrations [108–110]. Another step in oxidative stress signaling is the ROS-mediated increase of
cytosolic Ca2+ levels. Cytosolic Ca2+ plays a role in activation of several signaling paths including
apoptotic processes [111]. Relatively small amounts of H2O2 are also able to induce the mRNA of
the protein c-Fos and c-Jun which form the transcription factor AP-1 that is involved in cell growth,
differentiation, and apoptosis [112]. Activation of the mentioned pathways might not be enough to
promote a cytotoxic response after treatment, because they are involved in the complex regulation
system of several interfering signaling processes. Nevertheless, our results show that the combination
of both oxidative stress (low-dose H2O2) and drug-induced blockage of growth signaling pathways
enhance each other’s property to induce apoptosis in tumor cells. We identified three protein kinase
inhibitors that, in combination with low-dose H2O2, showed synergistic toxicity (terminally dead cells)
in colorectal carcinoma cells (CT26) in 2D and 3D tumor models. These substances were B9: lavendustin
A, D7: GF109203X, (G4: ZM449829 but only in 2D cultures), and H8: rapamycin. The effectiveness
of two of these substances, GF109203X and rapamycin, was validated in a 3D tumor model of HT29
and SW480 colorectal, as well as Panc01 pancreatic cancer cells (while D7: GF109203X failed to induce
constant significant changes in MiaPaca pancreatic cancer cells). The most potent toxic effect was found
in the combination of H2O2 with the substance H8: rapamycin, the weakest with B9: lavendustin A.
Our results indicated differences across several assays worth mentioning. For example, addressing
metabolic activity cannot differentiate between cytostatic and cytotoxic effects, and it was interesting to
note that the drugs alone were cytostatic (which was also observed in assaying cell area and cell cycle
phases), while drugs combined with low-dose H2O2 were cytotoxic. In oncology, a combination of both
effects is desired as both reduced proliferation [113], as well as cytotoxic effects, contribute to tumor
control [114]. This is of added value as many tumor cells acquire mutations to circumvent such an
arrest [115]. Moreover, oxidation of intracellular proteins, such as H2O2, can lead to such persistence in
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the G2 phase [116]. These oxidized proteins and the arrest of the cell cycle are central features of cellular
senescence [72,73] and may work in concert with chemotherapeutics [117]. Oxidative reactions within
the cell not only lead to direct protein modifications but also act on redox signaling pathways [118]
that regulate, for instance, rapid remodeling of the cytoskeleton [119,120]. Concordant with that, we
observed characteristic morphological changes in the different treatment regimens. Exposure to H2O2
alone provoked a slightly elongated phenotype in cancer cells. As subtoxic concentrations of ROS
can stimulate cellular proliferation this could speak for a more mesenchymal-like phenotype of the
cells [121]. Contrarily, the combinational treatment of H2O2 with different protein kinase inhibitors
showed a more rounded morphology of the cells. As already mentioned, together with our observation
of decreased cell growth and increase in individual cell size this could indicate cellular senescence [122].
A valuable tool to assess novel combination treatment avenues is the use of 3D tumor cell
spheroids [123]. In such structures, tumor cells show a more regulated proliferation and differentiation
behavior [124,125]. Similar to tumor nodules, spheroids can cause central necrosis by rapidly growing
tumor cells [126]. To what extent a substance is effective against spheroids does not only depend on its
intrinsic cytotoxic effect but also on its potential to diffuse into deep cell layers [127]. Thus, for example,
the kinase inhibitor G4: ZM449829 neither showed a cytotoxic effect in combination with H2O2 nor
when used alone, although substantial toxicity was observed in 2D cell culture experiments. The D7:
GF109203 and in particular H8: rapamycin showed a robust toxic effect in the 3D tumor spheroids,
which was also significantly increased in combination with H2O2 compared to single treatment with
the substance. These results seem promising for testing such a combination regimen further, despite
the lack of immunogenic features of our treatment. Engagement of antitumor immunity is an approach
receiving increasing interest in oncology [128]. An anti-tumor immune response evoked in the context
of ICD via DAMP release contributing to the maturation of dendritic cells [129,130] may lead to an
improvement in the prognosis of various cancers [97]. Even though pro-oxidative therapies are capable
of inducing ICD [131–133], we did not find an ICD signature common to all four combinations of
protein kinase inhibitors with H2O2. The reason for this could be that the oxidative stress-mediated by
H2O2 alone was cytostatic but not cytotoxic, while ICD requires the cells to die upon treatment [134].
Chemotherapeutic agents most commonly used in HIPEC are doxorubicin, mitomycin-C, cisplatin,
as well as combinations of cisplatin and mephedrone [135]. One aim of this work was to identify
other substances, which may add efficacy to the HIPEC treatment regime. Of these substances,
B9: lavendustin A, a non-competitive inhibitor of the ATP binding pocket of the EGFR kinase [136],
has already shown toxic effects on other types of tumor cells [137]. Moreover, Lavendustin A reduced
neovascularization in a rat model, potentially reducing the engraftment of new vessels in tumors [138].
For D7: GF109203X, an inhibitor of protein kinase C, reduced migration and invasion of lung carcinoma
cells was reported [139,140]. However, the same substance showed an increased proliferation of
endometrial cancer [141]. The substance G4: ZM449829, a Jak3 inhibitor that failed to give cytotoxic
effects in the 3D colorectal cancer model, may lead to immunosuppression due to reduced T cell
proliferation [142,143]. The toxic tumor effect of this substance on various cancer cells is currently
being investigated in other screenings campaigns [144,145]. A well-investigated drug inhibiting mTOR
complex I is H8: rapamycin. This substance performed best in our study. It is not only used as
anticancer drug but also to avoid graft rejection due to its immunosuppressive effect that may be
promoted due to its increase of regulatory T-cells and increased sensitivity towards apoptosis of
effector T-cells [146,147]. This fact may also explain the limited immunogenicity conferred either
alone or in combination with low-dose H2O2 as observed in our study. mTOR affects a variety of
signaling pathways, making it one of the most important regulators of cell growth [148]. Rapamycin
has already been shown to have potent toxic effect on various types of tumor cells [149–151], as well as
in colorectal carcinoma [152]. Notably, this substance is already being used as a chemotherapeutic agent
in HIPEC [153,154]. However, its application is often limited by resistances to rapamycin [146,155].
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4. Materials and Methods
4.1. Cell Cultivation
The colorectal carcinoma cells (CT26), derived from murine fibroblasts, were cultivated in Roswell
Park Memorial Insitute (RPMI) 1640 medium (PanBiotech, Aidenbach, Germany), containing 10%
fetal calf serum, 2% penicillin-streptomycin, and 2% glutamine (all Sigma-Aldrich, St. Louis, MI,
USA). The same culture medium was applied to the human colorectal adenocarcinoma cell line,
SW40. The human HT29 adenocarcinoma cells and human MiaPaca and Panc01 pancreatic epitheloid
carcinoma cells were cultured in Dulbecco’s modified Eagle medium (DMEM; ThermoFisher, Waltham,
MA, USA), containing equal supplements as described for RPMI. Cell splitting was performed regularly
twice a week using phosphate-buffered saline (PBS), accutase (BioLegend, London, United Kingdom),
and a cell culture incubator (Binder, Neckarsulm, Germany) at 37◦ C, 5% CO2, and 95% humidity.
For counting live cells, cells were stained with PI and quantitatively measured via an acoustically
focused flow cytometer (attune; ThermoFisher). For experiments with 2D-cell cultures, 1 × 104 cells
were seeded in 96◦ cell culture plates (Eppendorf, Hamburg, Germany) containing a rim that was
filled with double-distilled water for enhanced evaporation protection of the outer wells (edge effect).
To from 3D-tumor spheroids, 3 × 103 cells were seeded in ultra-low attachment plates (PerkinElmer,
Hamburg, Germany). For flow cytometry experiments, 1 × 105 cells were seeded in 24-well cell culture
plates with a water-filled rim to protect from edge effects (Eppendorf). Cells were incubated 24 h
before they were utilized for further experimental processing.
4.2. Treatment Regimen
The 80 different protein kinase inhibitors were from a compound library (Enzo, Farmingdale,
NY, USA) that was stored at −80 ◦C. To avoid repetitive freeze-thawing cycles, the samples were
aliquoted to their working concentration and stored in separate working plates, which were thawed
immediately before utilizing them for downstream assays. For treating the cells, the cell culture medium
was removed and replaced with either 50 µM H2O2 or with the different inhibitors at their specific
concentration for 15 min. Subsequently, the complementary treatment solution (either 50 µM H2O2 or
the substances) were added to the cells for 24 h. Through this procedure, it was tested if cells behave
differently upon receiving H2O2 either before or after the initial exposure to the kinase-inhibitors.
4.3. Plasma Treatment
To outline cold physical plasma as another method to induce hydrogen peroxide plasma treatment
was performed using the kINPen (neoplas) and Plasma Soft Jet (engineered at the Plasma Bioscience
Research Center, PBRC, Seoul, South Korea) argon plasma jets. These devices operate with 99.999%
argon gas (Air Liquide, Paris, France), at two standard liters per minute. During the treatment,
the gas flow, hight of the jets, and driving properties were standardized via an xyz-table (CNC-step,
Geldern, Germany). The treatment of the cells was carried out in 96-well plates with 100 µL cell
culture medium. The same amount of medium was used to quantify the levels of deposited hydrogen
peroxide in the liquid post-treatment using the Amplex Ultra Red (ThermoFisher) assay according to
the manufacturers’ instructions.
4.4. Metabolic Activity
After receiving the different substances from the kinase-inhibitor library (+/− H2O2), the cells
were stored at optimal growing conditions for 24 h hours before resazurin (Alfa Aesar, Haverhill, MA,
USA) was added at a final concentration of 100 µM. This metabolite can be converted by viable active
cells to the fluorescent resorufin. The fluorescence of resorufin was then quantified using a multiplate
reader (Tecan, Männedorf, Switzerland) at λex 560 nm and λem 590 nm. Normalization was performed
depending on the experimental question to either the untreated control or H2O2 alone.
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4.5. Quantitative High Content Imaging Analysis
To assess the cytotoxicity of the various treatment regimens in more detail, analysis by high
content imaging microscopy was performed. For this, the cells were incubated with 2.5 µM of a Sytox
Green or Blue (ThermoFisher) solution for 10 min at 37 ◦C. Sytox Green and Blue binds to nuclear
acids of dead cells that have lost their membrane integrity. Image acquisition was made using the high
content/high throughput-imaging device Operetta CLS (PerkinElmer). The device acquires images
with a 4.7-megapixel 16-bit sCMOS camera and using laser-based autofocus for high precision planarity.
For the investigation of cell viability and morphology in 96-well plates, a 20x air objective (NA = 0.4;
Zeiss, Jena, Germany) was used. For the microscopy of spheroids, a 5× air objective (NA = 0.16, Zeiss)
was used. In the 96-well plates, several single images were taken per well in at least nine fields of view
(FOVs). Different excitation LEDs were used to capture brightfield (BF) and digital-phase-contrast
(DPC) images. For fluorescence microscopy, a λex 475 nm LED with a λem 525 ± 25 nm bandpass filter
or a λex 405 nm LED with a λem 465 ± 35 nm bandpass filter was used to measure Sytox Green and
Sytox Blue intensity levels. In preliminary experiments, all image acquisitions were optimized in favor
of a well-focused image and optimum signal-to-noise ratio, and a standardized recording setup was
created to assure precise imaging experiments across longitudinal experiments. Both the measurement
and the subsequent analysis of the images were performed using the Harmony 4.9 (PerkinElmer)
setup and analysis software. The evaluation strategy of the Sytox stain included a combination of the
captured images of the fluorescence channel and the DPC signal, which reflects the pseudo-cytosolic
cell surface. The latter allows for the segmentation of cells. At least 500 cells were segmented per well,
and approximately 2000 single wells were analyzed in this study. Specifically, a combined image from
both channels was used by the software segmenting objects for parameters such as intensity threshold
and individual threshold, size and coefficients for sharing different signals. This was preceded by
filtering the image by a sliding parabola function to increase the contrast and hence, segmentation
accuracy. Within the detected cells of each well, the intensity of the fluorescence signal and the
percentage of dead cells was calculated. Here, cells with relative mean fluorescence intensity (MFI) of
greater than 1500 fluorescence units and a sum intensity greater than 5000 fluorescence units were
considered as dead cells. Furthermore, various morphological parameters were calculated. All image
quantification strategies were completely algorithm-based without the possibility of user intervention
with regard to segmentation of, e.g., individual cells. Extended measurements were performed at
37 ◦C and 5% CO2 (live cell imaging) to avoid the toxic effects of unsuitable environmental conditions.
4.6. Flow Cytometry
To determine surface markers of ICD, 1 × 105 CT26 cells were seeded in 1 mL fully supplemented
cell culture medium in 24-well cell culture plates and incubated for 24 h. Subsequently, the cell
culture medium was incubated with the different protein kinase inhibitors alone or in combination
with H2O2 for another 24 h. Subsequently, cells were washed with 1 mL of PBS, and incubated with
an antibody mix targeted against HSP70 conjugated to Alexa Fluor (AF) 488 (Abcam, Cambridge,
United Kingdom), CRT (Novus, Littleton, CO, USA) conjugated to allophycocyanin (APC), HSP70
conjugated to AF700 (Novus), HMGB1 (BioLegend) conjugated to phycoerythrin (PE), the nucleic acid
stain 4′,6-Diamidino-2-phenylindole (DAPI; BioLegend), and the accutase. Cells were incubated for
30 min at 37 ◦C before transferring the cell suspension to a 96 well v-bottom plate (Eppendorf). After
centrifugation at 500× g for 5 min, cells were resuspended in PBS and washed twice before being taken
up in a final volume of 75 µL per well. Individual cells of the suspension were acquired with a 4-laser
flow cytometer equipped with a plate loader autosampler (CytoFLEX S; Beckman-Coulter, Brea, CA,
USA) using CytExpert 2.0 software (Beckman-Coulter) as acquisition software. Forward scatter (FS)
and side scatter (SSC), as well as the fluorescence of AF488, PE, APC, AF700, and DAPI was collected
using specific band-bass filters. The spillover matrix was pre-determined using single-stained cells
and setup beads (ThermoFisher). For analysis, the geometric mean values for each fluorochrome was
determined in the live cell population, and exported for statistical evaluation. To analyze the different
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cell cycle phases, cells were treated and incubated as described above. After incubation, cells were
detached, washed in PBS, and fixed with −20 ◦C ethanol for one hour. Subsequently, cells were washed
and incubated with DAPI (final concentration 10 µM) for 30 min at 37 ◦C. After two further washes,
single cells were acquired using flow cytometry. Analysis of FCS-files was performed using Kaluza 2.1
analysis software (Beckman-Coulter). This software contains a plug-in that allows determining cell
cycle phases via an algorithm (Fox), overcoming the limitations of manual gating of cell cycle phases.
4.7. 3D Tumor Spheroids
To form three-dimensional tumor cell spheroids, 3 × 103 CT26, HT29, SW480, MiaPaca, or Panc01
cells were seeded in 150 µL fully supplemented cell culture medium in 96-well plates (ThermoFisher) that
prevent adhesion of cells by a special coating. Immediately after seeding, the suspension was centrifuged
at 1000× g for 10 min to force an accumulation of cells in the center of the round bottom well. After
incubation for 72 h, 125 µL of the cell culture medium was carefully removed and replaced with 50 µL of
the protein kinase inhibitors in the corresponding concentration. After 15 min of incubation under cell
culture conditions, 50 µL of a 50 µM H2O2 solution containing 2.5 µM of Sytox Green or Blue (with both
stain nucleic acids as an indicator for cell death) was added. Immediately after that, as well as after 12 h,
24 h, 48 h, and 72 h of incubation, all spheroids were sequentially examined using high content imaging.
The settings of the measurements were also standardized using a previously established measurement
template. For image acquisition, taking into account the three-dimensional structure of such tumor cell
nodules, 15 z-plane images (distance between planes: 5 µm) were acquired. For analysis, maximum
intensity projections (MIP) were calculated for each spheroid to give 2.5D images. For enhanced
contrasting and delimiting the spheroid from the background, a sliding parabola function was used.
Subsequently, intensities of the Sytox fluorescence channel as well as morphological parameters were
calculated using algorithm-based quantitative imaging tools. The morphology parameter “compactness”
was also calculated using a morphology tool (STAR-morphology) that is provided by the Harmony 4.9
(PerkinElmer) analysis software. This utilizes the distribution of signals inside the brightfield channel
(that absorbs more light than 60% of the average spheroid signal = compact regions) in comparison to
the border of the spheroid region. Such compact spheroids get a high ‘compactness’ value, while this is
low for spheroids composed of loose cells.
4.8. Statistical Analysis
Graphing and statistical evaluation were done using Prism 8.2 (GraphPad software, San Diego, CA,
USA). Unless otherwise indicated, mean or standard error (SEM) is shown on the graphs. Mean values
were obtained from individual data points of technical and biological replicates for the experiments on
viability (resazurin assay) or from measurements for approximately 1 × 104 individual cells in FACS
or 5–10 × 103 cells per well in high content imaging experiments. To avoid the accumulation of the
α-error, one-way analysis of variance (ANOVA) or Kruskal–Wallis test was used as a non-parametric
alternative for the statistical analysis comparing more than two groups. If several conditions were
compared within several groups, a multi-factorial analysis of variance (ANOVA II) was used. Post-doc
testing was done using Dunnett’s test. Trends were considered significant from the 95% confidence
interval. Levels of significance were given as follows: * α = 0.05; ** α = 0.01; *** α = 0.001.
5. Conclusions
Tyrosine kinase inhibitors are potent anticancer drugs, but chemoresistance may limit its use.
Targeting both tyrosine kinase activity and oxidative stress pathways simultaneously, we identified two
potent combinations that led to synergistic toxicity in 2D and 3D colorectal cell culture models. The most
effective combination was low-dose H2O2 together with rapamycin. As this drug is already utilized
in HIPEC targeting diffuse colorectal peritoneal carcinomatosis, such an approach may complement
existing therapies of colorectal cancer.
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